Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.185

+1.3%

2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who started this subject	11/13/2003 8:54:44 AM
From: tom pope	Read Replies (1) of 3576

From CBS Marketwatch Geron Announces Presentation of Preclinical Studies on Human Embryonic Stem Cell-Based Treatment of Acute Spinal Cord Injury 11/13/2003 7:31:00 AM MENLO PARK, Calif., Nov 13, 2003 (BUSINESS WIRE) -- Geron Corporation (GERN) today announced the presentation of results demonstrating that the transplant of cells differentiated from human embryonic stem cells (hESCs) can result in functional improvement in animals with spinal cord injuries. This work provides proof of concept of the efficacy of hESC-based therapies in spinal cord injury. full story at cbs.marketwatch.com{93B8C30D-DBCA-4E96-8718-2CE11A57B0E3}&siteid=mktw

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next